Acute Myeloid Leukemia: Current and Emerging Therapies and Market Consideration in the World

Acute myeloid leukemia (AML) is an aggressive, fast-growingcancer beginning inside bone marrow and spreading into the bloodsystem, most often occurring in immature white blood cells. It has thelowest five-year survival rate among other types of leukemia and ifleft untreated, it can be fatal. Even though there have been significantimprovements in the treatment of other related subtypes, AMLtargetedtherapy development have been limited. The current marketfor AML drugs cannot fill the high unmet needs in terms of drug safetyand efficacy, and the growing aging population presents increasedopportunities for new drugs. Considering these driving forces, it isbelieved that promising opportunities exist for new entrants to capturevalue from underserved segments of the market. It is estimated thatthe market size for AML drugs in 2020 will reach US$1.67 billionwith an average annual growth of nearly 23%. Therefore, it is highlyrecommended for pharmaceutical companies to invest in this area ofdrug development as soon as possible in order to maximize gains fromtheir investments as novel therapeutics enter the AML market at arapid pace.

Acute myeloid leukemia (AML) is an aggressive, fast-growing cancer beginning inside bone marrow and spreading into the blood system, most often occurring in immature white blood cells. It has the lowest five-year survival rate among other types of leukemia and if left untreated, it can be fatal. Even though there have been significant improvements in the treatment of other related subtypes, AMLtargeted therapy development have been limited. The current market for AML drugs cannot fill the high unmet needs in terms of drug safety and efficacy, and the growing aging population presents increased opportunities for new drugs. Considering these driving forces, it is believed that promising opportunities exist for new entrants to capture value from underserved segments of the market. It is estimated that the market size for AML drugs in 2020 will reach US$1.67 billion with an average annual growth of nearly 23%. Therefore, it is highly recommended for pharmaceutical companies to invest in this area of drug development as soon as possible in order to maximize gains from their investments as novel therapeutics enter the AML market at a rapid pace